Compare $DRMA vs $LIMN | Chartloom

Compare

$DRMA vs $LIMN

Dermata Therapeutics Inc · Liminatus Pharma Inc

DRMA

Dermata Therapeutics Inc

LIMN

Liminatus Pharma Inc

Compare $DRMA vs $LIMN

Comparing Dermata Therapeutics Inc and Liminatus Pharma Inc

DRMADermata Therapeutics Inc

LIMNLiminatus Pharma Inc

DRMADermata Therapeutics Inc

Market cap

$4M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

11.49x

Rev growth (TTM)

—

YTD performance

-53.2%

52W performance

-78.7%

FCF yield

-198.6%

LIMNLiminatus Pharma Inc

Market cap

$253M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-88.3%

52W performance

-95.3%

FCF yield

-1.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DRMA

LIMN

Detailed metrics comparison

DRMA

Dermata Therapeutics Inc

LIMN

Liminatus Pharma Inc

Market Cap

DRMA$4M

LIMN$253M

Enterprise Value

DRMA$-312K

LIMN$251M

Price

DRMA$1.02

LIMN$3.76

P/E Ratio

DRMAN/A

LIMNN/A

P/S Ratio

DRMA0.00x

LIMN0.00x

EV/Sales

DRMA0.00x

LIMN0.00x

EV/EBITDA

DRMA0.00x

LIMN0.00x

P/B Ratio

DRMA1.27x

LIMN17.43x

P/FCF Ratio

DRMAN/A

LIMNN/A

EV/FCF

DRMA0.04x

LIMN-62.96x

PEG Ratio

DRMAN/A

LIMNN/A

Forward P/E (NTM)

DRMAN/A

LIMNN/A

Forward P/S (NTM)

DRMA11.49x

LIMNN/A

Revenue (TTM)

DRMA$0

LIMN$0

Revenue Growth (YoY)

DRMAN/A

LIMNN/A

Forward Rev Growth

DRMA650.0%

LIMN0.0%

Gross Margin (TTM)

DRMA0.0%

LIMN0.0%

Operating Margin (TTM)

DRMA0.0%

LIMN0.0%

EBITDA Margin (TTM)

DRMA0.0%

LIMN0.0%

Net Margin (TTM)

DRMA0.0%

LIMN0.0%

FCF Margin (TTM)

DRMAN/A

LIMNN/A

Net Income (TTM)

DRMA$-8M

LIMN$-13M

FCF (TTM)

DRMA$-8M

LIMN$-4M

EPS (TTM)

DRMA-$2.08

LIMN-$12.94

ROE (TTM)

DRMA-16667.0%

LIMN0.0%

ROA (TTM)

DRMA-13014.0%

LIMN-62234.0%

ROIC (TTM)

DRMA-16667.0%

LIMN0.0%

Cash

DRMA$4M

LIMN$3M

Debt

DRMA$0

LIMN$1M

Net Cash/Debt

DRMA$4M

LIMN$2M

Current Ratio (TTM)

DRMA2.81x

LIMN1.12x

Quick Ratio (TTM)

DRMA2.62x

LIMN0.99x

Debt/Equity (TTM)

DRMA0.00x

LIMN4.80x

Debt/Assets (TTM)

DRMA0.0%

LIMN0.0%

Interest Coverage (TTM)

DRMAN/A

LIMNN/A

Net Debt/EBITDA (TTM)

DRMA0.00x

LIMN0.00x

Beta

DRMA0.58

LIMN0.75

52W Performance

DRMA-78.7%

LIMN-95.3%

YTD Performance

DRMA-53.2%

LIMN-88.3%

% from 52W High

DRMA-78.9%

LIMN-97.3%

% from 52W Low

DRMA7.3%

LIMN14.3%

Asset Turnover (TTM)

DRMA0.00x

LIMN0.00x

FCF Yield (TTM)

DRMA-198.6%

LIMN-1.6%

Earnings Yield (TTM)

DRMA-204.1%

LIMN-5.0%

Dividend Yield (TTM)

DRMAN/A

LIMNN/A

Rule of 40

DRMA0.0

LIMN0.0

EV/GP/RG

DRMAN/A

LIMNN/A

Ticker research

View DRMA research View LIMN research

Metric	DRMA Dermata Therapeutics Inc	LIMN Liminatus Pharma Inc
Market & Valuation
Market Cap	$4M	$253M
Enterprise Value	$-312K	$251M
Price	$1.02	$3.76
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.27x	17.43x
P/FCF Ratio	N/A	N/A
EV/FCF	0.04x	-62.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	11.49x	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	650.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-8M	$-13M
FCF (TTM)	$-8M	$-4M
EPS (TTM)	-$2.08	-$12.94
ROE (TTM)	-16667.0%	0.0%
ROA (TTM)	-13014.0%	-62234.0%
ROIC (TTM)	-16667.0%	0.0%
Financial Health
Cash	$4M	$3M
Debt	$0	$1M
Net Cash/Debt	$4M	$2M
Current Ratio (TTM)	2.81x	1.12x
Quick Ratio (TTM)	2.62x	0.99x
Debt/Equity (TTM)	0.00x	4.80x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.58	0.75
52W Performance	-78.7%	-95.3%
YTD Performance	-53.2%	-88.3%
% from 52W High	-78.9%	-97.3%
% from 52W Low	7.3%	14.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-198.6%	-1.6%
Earnings Yield (TTM)	-204.1%	-5.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View DRMA research	View LIMN research

Valuation

P/S Ratio

DRMA

0.00x

LIMN

0.00x

EV/FCF

LIMN

-62.96x

DRMA

0.04x

Growth & revenue

Forward Revenue Growth

DRMA

650.0%

LIMN

0.0%

Profitability & performance

Gross Margin

DRMA

0.0%

LIMN

0.0%

ROE

LIMN

0.0%

DRMA

-16667.0%

FCF Yield %

LIMN

-1.6%

DRMA

-198.6%

52-Week Performance

DRMA

-78.7%

LIMN

-95.3%

Detailed metrics comparison

DRMA

Dermata Therapeutics Inc

LIMN

Liminatus Pharma Inc

Market Cap

DRMA$4M

LIMN$253M

Enterprise Value

DRMA$-312K

LIMN$251M

Price

DRMA$1.02

LIMN$3.76

P/E Ratio

DRMAN/A

LIMNN/A

P/S Ratio

DRMA0.00x

LIMN0.00x

EV/Sales

DRMA0.00x

LIMN0.00x

EV/EBITDA

DRMA0.00x

LIMN0.00x

P/B Ratio

DRMA1.27x

LIMN17.43x

P/FCF Ratio

DRMAN/A

LIMNN/A

EV/FCF

DRMA0.04x

LIMN-62.96x

PEG Ratio

DRMAN/A

LIMNN/A

Forward P/E (NTM)

DRMAN/A

LIMNN/A

Forward P/S (NTM)

DRMA11.49x

LIMNN/A

Revenue (TTM)

DRMA$0

LIMN$0

Revenue Growth (YoY)

DRMAN/A

LIMNN/A

Forward Rev Growth

DRMA650.0%

LIMN0.0%

Gross Margin (TTM)

DRMA0.0%

LIMN0.0%

Operating Margin (TTM)

DRMA0.0%

LIMN0.0%

EBITDA Margin (TTM)

DRMA0.0%

LIMN0.0%

Net Margin (TTM)

DRMA0.0%

LIMN0.0%

FCF Margin (TTM)

DRMAN/A

LIMNN/A

Net Income (TTM)

DRMA$-8M

LIMN$-13M

FCF (TTM)

DRMA$-8M

LIMN$-4M

EPS (TTM)

DRMA-$2.08

LIMN-$12.94

ROE (TTM)

DRMA-16667.0%

LIMN0.0%

ROA (TTM)

DRMA-13014.0%

LIMN-62234.0%

ROIC (TTM)

DRMA-16667.0%

LIMN0.0%

Cash

DRMA$4M

LIMN$3M

Debt

DRMA$0

LIMN$1M

Net Cash/Debt

DRMA$4M

LIMN$2M

Current Ratio (TTM)

DRMA2.81x

LIMN1.12x

Quick Ratio (TTM)

DRMA2.62x

LIMN0.99x

Debt/Equity (TTM)

DRMA0.00x

LIMN4.80x

Debt/Assets (TTM)

DRMA0.0%

LIMN0.0%

Interest Coverage (TTM)

DRMAN/A

LIMNN/A

Net Debt/EBITDA (TTM)

DRMA0.00x

LIMN0.00x

Beta

DRMA0.58

LIMN0.75

52W Performance

DRMA-78.7%

LIMN-95.3%

YTD Performance

DRMA-53.2%

LIMN-88.3%

% from 52W High

DRMA-78.9%

LIMN-97.3%

% from 52W Low

DRMA7.3%

LIMN14.3%

Asset Turnover (TTM)

DRMA0.00x

LIMN0.00x

FCF Yield (TTM)

DRMA-198.6%

LIMN-1.6%

Earnings Yield (TTM)

DRMA-204.1%

LIMN-5.0%

Dividend Yield (TTM)

DRMAN/A

LIMNN/A

Rule of 40

DRMA0.0

LIMN0.0

EV/GP/RG

DRMAN/A

LIMNN/A

Ticker research

View DRMA research View LIMN research

Metric	DRMA Dermata Therapeutics Inc	LIMN Liminatus Pharma Inc
Market & Valuation
Market Cap	$4M	$253M
Enterprise Value	$-312K	$251M
Price	$1.02	$3.76
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.27x	17.43x
P/FCF Ratio	N/A	N/A
EV/FCF	0.04x	-62.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	11.49x	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	650.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-8M	$-13M
FCF (TTM)	$-8M	$-4M
EPS (TTM)	-$2.08	-$12.94
ROE (TTM)	-16667.0%	0.0%
ROA (TTM)	-13014.0%	-62234.0%
ROIC (TTM)	-16667.0%	0.0%
Financial Health
Cash	$4M	$3M
Debt	$0	$1M
Net Cash/Debt	$4M	$2M
Current Ratio (TTM)	2.81x	1.12x
Quick Ratio (TTM)	2.62x	0.99x
Debt/Equity (TTM)	0.00x	4.80x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.58	0.75
52W Performance	-78.7%	-95.3%
YTD Performance	-53.2%	-88.3%
% from 52W High	-78.9%	-97.3%
% from 52W Low	7.3%	14.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-198.6%	-1.6%
Earnings Yield (TTM)	-204.1%	-5.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View DRMA research	View LIMN research